Overview

A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Status:
Not yet recruiting
Trial end date:
2029-07-25
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to compare CC-92480 (BMS-986348) with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Dexamethasone
Criteria
Inclusion Criteria:

- Participant has documented diagnosis of multiple myeloma and measurable disease,
defined as any of the following:

- Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein
electrophoresis (sPEP), or

- M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein
electrophoresis (uPEP) or,

- For participants without measurable disease in sPEP or uPEP: serum free light
chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal
κ/λ free light chain ratio .

- Participant has received at least one prior line of anti-myeloma therapy. Note: One
line can contain several phases (e.g., induction, [with or without] hematopoietic stem
cell transplant, (with or without) consolidation, and/or [with or without] maintenance
therapy).

- Participant must have received prior treatment with lenalidomide and an anti-CD38
monoclonal antibody.

- Participant achieved minimal response or better to at least 1 prior anti-myeloma
therapy.

- Participant must have documented disease progression during or after their last
antimyeloma regimen.

Exclusion Criteria:

- Participant who has had prior treatment with CC-92480 or carfilzomib.

- Participant has previously received allogeneic stem cell transplant at any time or
received autologous stem cell transplant within 12 weeks of initiating study
treatment.

Additional protocol-defined criteria apply.